Multicenter Evaluation of Patients with Cutaneous Malignant Melanoma in Turkey: MELAS Study |
Uysal-Sonmez, Ozlem
(Department of Medical Oncology, Sakarya University Education and Research Hospital)
Tanriverdi, Ozgur (Department of Medical Oncology, Mugla Sitki Kocman University Education and Research Hospital) Esbah, Onur (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) Uyeturk, Ummugul (Division of Medical Oncology, Department of Internal Medicine, Abant Izzet Baysal University Faculty of Medicine) Helvaci, Kaan (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) Bal, Oznur (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) Yalcintas-Arslan, Ulku (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) Budakoglu, Burcin (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) Oksuzoglu, Berna (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) |
1 | Hainsworth JD, Infante JR, Spigel DR, et al (2010). Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah cannon oncology research consortium. Cancer, 116, 4122-9. DOI ScienceOn |
2 | Hauschild A, Agarwala SS, Trefzer U, et al (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol, 27, 2823-30. DOI ScienceOn |
3 | Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. DOI ScienceOn |
4 | Lasithiotakis K, Leiter U, Meier F, et al (2008). Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer, 112, 1795-804. DOI ScienceOn |
5 | Lindholm C, Andersson R, Dufmats M, et al (2004). Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors. Cancer, 101, 2067-78. DOI ScienceOn |
6 | MacKie RM, Bray C, Vestey J, et al (2007). Melanoma incidence and mortality in Scotland 1979-2003. Br J Cancer, 96, 1772-7. DOI ScienceOn |
7 | Markovic SN, Erickson LA, Rao RD, et al (2007). Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc, 82, 490-513. DOI ScienceOn |
8 | Mervic L (2012). Prognostic factors in patients with localized primary cutaneous melanoma. Acta Dermatovenerologica, 21, 27-31. |
9 | O'Day S, Hodi FS, McDermott DF, et al (2010). A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol, 28, 4. DOI |
10 | Reed KB, Brewer JD, Lohse CM, et al (2012). Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc, 87, 328-34. DOI ScienceOn |
11 | Spatz A, Cook MG, Elder DE, et al (2003). Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. Eur J Cancer, 39, 1861-5. DOI ScienceOn |
12 | Tas F, Kurul S, Camlica H, Topuz E (2006). Malignant melanoma in Turkey: a single institution’s experience on 475 cases. Jpn J Clin Oncol, 36, 784-9. |
13 | Thompson JF, Soong SJ, Balch CM, et al (2011). Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American joint committee on cancer melanoma staging database. J Clin Oncol, 29, 2199-205. DOI ScienceOn |
14 | Uehara S, Kamo R, Harada T, Ishii M (2009). Survival analysis of malignant melanoma in Japan-multivariate analysis of prognostic factors. Osaka City Med J, 55, 35-52. |
15 | Verma S, Quirt I, McCready D, et al (2006). Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer, 106, 1431-42. DOI ScienceOn |
16 | Balch CM, Buzaid AC, Soong SJ, et al (2001). Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol, 19, 3635-48. |
17 | Barnhill RL, Fine JA, Roush GC, Berwick M (1996). Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer, 78, 427-32. DOI ScienceOn |
18 | Chao C, Martin RC, Ross MI, et al (2004). Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol, 11, 259-64. DOI ScienceOn |
19 | Gimotty PA, Botbyl J, Soong SH, Guerry D (2005). A population-based validation of the American Joint Committee on Cancer melanoma staging systemç. J Clin Oncol, 23, 8065-75. DOI ScienceOn |
20 | Chi Z, Li S, Sheng X, et al (2011). Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer, 11, 85-95. DOI ScienceOn |
![]() |